Benzalkonium Chloride: A Bronchoconstricting Preservative in Continuous Albuterol Nebulizer Solutions
| Autor: | Leslie Hendeles, Sreekala Prabhakaran, Mutasim Abu-Hasan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Preservative
medicine.drug_class Bronchoconstriction Bronchospasm 03 medical and health sciences Benzalkonium chloride 0302 clinical medicine immune system diseases 030225 pediatrics Bronchodilator medicine Humans Albuterol Pharmacology (medical) Adverse effect Randomized Controlled Trials as Topic Dose-Response Relationship Drug business.industry Nebulizers and Vaporizers Preservatives Pharmaceutical Airway obstruction medicine.disease Bronchodilator Agents respiratory tract diseases Nebulizer 030228 respiratory system Anesthesia medicine.symptom Benzalkonium Compounds business Airway responsiveness medicine.drug |
| Zdroj: | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 37:607-610 |
| ISSN: | 0277-0008 |
| DOI: | 10.1002/phar.1929 |
| Popis: | For convenience, many pediatric hospitals are preparing solutions for continuous nebulized albuterol using the 0.5% 20-ml multidose albuterol dropper bottle. This product contains benzalkonium chloride (BAC) that, by itself, produces bronchospasm that is dose dependent and cumulative. The bronchoconstrictive effects of BAC are greater in patients with more severe airway obstruction and increased airway responsiveness. Use of BAC-containing albuterol during severe acute asthma exacerbations may antagonize the bronchodilator response to albuterol, prolong treatment, and increase the risk of albuterol-related systemic adverse effects. Such a deleterious effect of BAC is difficult to detect because some patients improve slowly or may even worsen during treatment. We recommend that only preservative-free albuterol products be used. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text